Literature DB >> 28501120

Histologic lung cancer subtype differentiates synchronous multiple primary lung adenocarcinomas from intrapulmonary metastases.

Hua Cheng1, Bin-Feng Lei2, Pei-Jian Peng3, Yu-Jing Lin4, Xiao-Jin Wang3.   

Abstract

BACKGROUND: Distinguishing synchronous multiple primary lung cancers (SMPLCs) from intrapulmonary metastases is important. The objective of this study was to determine long-term survival in patients who underwent surgical resection for synchronous multiple lung cancers and identify additional criteria that may be useful to distinguish patients with SMPLCs from those with more advanced disease.
METHODS: The medical records of patients with lung cancer who underwent planned resection for synchronous multiple lung cancers from 2007 to 2012 at our institutions were reviewed retrospectively. A comprehensive histologic assessment was used to determine whether the tumors were metastases or separate synchronous primary tumors.
RESULTS: A total of 51 patients with synchronous multiple lung cancers underwent surgical resection. Twenty-nine patients had ipsilateral synchronous multiple lung cancers, and 22 had bilateral synchronous multiple lung cancers. No perioperative death occurred. The survival analysis of all 51 patients with synchronous multiple lung cancers who underwent planned resection of all lesions showed 3- and 5-year overall survival rates of 86% and 67%, respectively, The median overall survival was not reached. The comprehensive histologic assessment identified six patients with intrapulmonary metastasis and 45 patients with SMPLCs. Intrapulmonary metastases were associated with decreased survival. Among patients with SMPLCs, the epidermal growth factor receptor mutation distribution shown high concordant frequency rate of 35% (5/14).
CONCLUSIONS: Survival after surgical resection of synchronous multiple lung cancers in different lobes was promising. A comprehensive histologic assessment was useful for differentiating SMPLCs from intrapulmonary metastases.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Comprehensive histological assessmenttherapy; Lung cancer; Multiple primary lung cancer

Mesh:

Year:  2016        PMID: 28501120     DOI: 10.1016/j.jss.2016.11.050

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.

Authors:  Hiroaki Kodama; Tatsuya Ibe; Rentaro Inoue; Tetsuya Shimada; Hisashi Ishii; Yoichiro Hamamoto
Journal:  Cancer Rep (Hoboken)       Date:  2020-08-11

2.  Whole exome sequencing of lung adenocarcinoma and lung squamous cell carcinoma in one individual: A case report.

Authors:  Yuxi Bai; Yinghui Xu; Xu Wang; Yunpeng Liu; Chao Sun; Ye Guo; Yangyang Cai; Guoguang Shao; Zhiguang Yang; Shi Qiu; Kewei Ma
Journal:  Thorac Cancer       Date:  2020-06-23       Impact factor: 3.500

3.  A comprehensive algorithm to distinguish between MPLC and IPM in multiple lung tumors patients.

Authors:  Jun Shao; Chengdi Wang; Jingwei Li; Lujia Song; Linhui Li; Panwen Tian; Weimin Li
Journal:  Ann Transl Med       Date:  2020-09

4.  Characteristics and prognosis of synchronous multiple primary lung cancer after surgical treatment: A systematic review and meta-analysis of current evidence.

Authors:  Hongtao Tie; Jun Luo; Rui Shi; Zhenhan Li; Dan Chen; Qingchen Wu
Journal:  Cancer Med       Date:  2020-12-10       Impact factor: 4.452

5.  Precise resection of multiple pulmonary nodules using a three-dimensional reconstruction model: A case report.

Authors:  Xiang-Peng Chu; Zi-Hao Chen; Shao-Min Lin; Wen-Fang Tang; Jia-Tao Zhang; Yao-Ming Lai; Rui Fu; Zhen-Bin Qiu; Jun-Tao Lin; Qiang Nie; Xue-Ning Yang; Yi-Long Wu; Wen-Zhao Zhong
Journal:  Thorac Cancer       Date:  2021-01-27       Impact factor: 3.500

6.  MTA1 Expression Can Stratify the Risk of Patients with Multifocal Non-Small Cell Lung Cancers ≤3 cm.

Authors:  Wei Wang; Zaoxiu Hu; Mingsheng Ma; Haoyuan Yin; Yunchao Huang; Guangqiang Zhao; Xin Cui; Qinling Sun; Yantao Yang; Yichen Yang; Biying Wang; Lianhua Ye
Journal:  Ther Clin Risk Manag       Date:  2021-12-03       Impact factor: 2.755

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.